An ADA-positive-specific NICE case for late-onset Pompe clears far more directly than competing on incremental FVC improvement against alglucosidase.

Alglucosidase alfa (Lumizyme/Myozyme, Sanofi) is NHS England's commissioned late-onset Pompe standard, delivered via clinical and commissioning policy rather than a formal NICE Technology Appraisal, reaching roughly 280-350 of the UK's 350-450 total Pompe patients at the 8 NHS Highly Specialised Service centres, anchored by Royal Free London's 80-100 patient cohort. Avalglucosidase alfa (Nexviazyme, Sanofi), the next-generation ERT, already has a positive NICE recommendation, TA821 from August 2022, defining the switch criteria for every subsequent submission. But the economics show how hard that comparator is to clear: a small QALY increment against a materially higher list price, resting on a confidential access scheme built on Sanofi's existing franchise, a position a new entrant without that installed base could not easily replicate.

A materially more favourable NICE case exists in the anti-drug-antibody-positive, or ADA+, inadequate-responder subgroup: an estimated 30-50 UK LOPD patients on alglucosidase develop high-titre ADA and experience measurable clinical deterioration despite continued ERT. A drug positioned specifically for this cohort is assessed against a baseline of ongoing deterioration rather than incremental improvement, and the QALY model shifts accordingly: avoiding ventilator dependency carries a large utility gain, roughly 0.36 QALY a year for each year of ventilation avoided. The 80-120 UK LOPD patients on home non-invasive ventilation, with FVC below 50% predicted and faster decline on inadequate ERT, represent the highest-urgency and strongest evidence-base subgroup for this positioning.

Without an identified ADA-positive population, there is no NICE-eligible cohort to submit.

Five questions this report answers:

Q1 - Should a new LOPD agent compete on FVC improvement or build a standalone ADA-positive case?

Q2 - How large is the UK ADA-positive and NIV-dependent LOPD population before approval?

Q3 - What BIMDG and Royal Free engagement sequence builds a UK ADA-positive NICE submission?

Q4 - What deliverable formats come with a commissioned UK Pompe launch readiness assessment?

Q5 - What must a pre-launch late-onset Pompe disease asset prove to succeed in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #LOPD #NICE #UKMarketAccess #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/pompe-disease/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/